Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL

Exclusion Criteria

• •Patients with a history of pancreatitis.
• •Active infection requires ICU treatment.
• •Concomitant HIV infection or active infection with HBV, HCV.
• •Serious complications such as fulminant DIC.
• •Significant organ dysfunction:
• •* respiratory failure
• •* NYHA classification≥2 chronic congestive heart failure
• •* decompensation Hepatic or renal insufficiency
• •* high blood pressure and diabetes that cannot be controlled
• •* cerebral vascular events within the past 6 months.
• •Pregnant and lactating women.
• •Had a history of autoimmune diseases, and disease was active now. Those who were known to be allergic to drugs in the study regimen.
• •Patients with other tumors who require treatments within 6 months.
• •Other experimental drugs are being used.